Encapsulated mesenchymal stem cells for in vivo immunomodulation
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Mesenchymal stem cells (MSCs) are self-renewable, multipotent progenitor cells able to differentiate into various mesodermal lineages. 1 MSCs are present in basically all tissues, and have a pivotal role in tissue repair and in local control of inflammation.
In vitro studies indicated that MSCs have immunomodulatory activities: they inhibit T and NK cell activation, B-cell terminal differentiation and dendritic cell maturation and functions. 2 Little is known about the action of MSCs in vivo but a recent report showed that MSCs affect dendritic cell homing to lymph nodes, thus impairing T-cell priming. 3 Although there is evidence from in vivo studies that MSCs are able to reduce inflammatory damage without engraftment, 4 it is not clear whether their immunomodulatory effects rely on soluble mediators or cell-cell contacts (reviewed in Yagi et al. 2 ). There is a growing interest in using MSCs to treat human inflammatory diseases, including severe (grade III-IV) steroid resistant acute graft versus host disease (aGVHD). Various trials reported non-homogeneous results, with MSCs responses varying from 15 to 55% of treated patients. Although a study using a large cohort of patients provided encouraging results (reviewed in Tolar et al.
5
), recent data could not confirm the efficacy of MSCs for the treatment of GVHD. 6 The reasons for these conflicting results are not clear and, among others, may include differences in the number of MSCs that remain viable in patients overtime, a critical factor that so far is very difficult to control.
Another critical aspect of MSC-based cell therapy is its safety, especially when considering long-term complications: MSCs may cause tumor formation 7, 8 or aberrantly differentiate after ectopic engraftment. 9 Finally, another risk factor is associated with the administration route. Indeed, although the number of MSCs required to achieve immunomodulation in vivo is basically unknown, injection of large number of cells may be necessary to obtain maximal clinical benefit given the low rate of cell retention and survival. In these conditions, MSCs may form aggregates that could cause pulmonary emboli or infarctions in patients. 10 Considering all these issues, we decided to study the immunomodulatory effects of encapsulated mouse MSCs (E-MSCs). Indeed, this procedure would allow not only to solve all safety problems related to MSCs administration, but also to design precise protocols in which cell viability, and therefore cell dosage, is standardized. Importantly, this approach might provide conclusive data in support of either the endocrine or the paracrine/contact hypothesis for the in vivo immunomodulatory activity of MSCs.
Alginate is the most commonly employed polymer for cell microencapsulation because of its excellent biocompatibility and in vivo stability. 11 MSCs derived from B6 mice were used for the preparation of alginate microcapsules that, when analyzed by optical microscopy, showed uniform and spherical morphology (Figure 1a) , with an average diameter of 600-700 mm. Staining with fluorescein diacetate and ethidium bromide showed that the microencapsulation procedure did not affect MSCs viability, even after 7 days of in vitro incubation (Figure 1b) . In order to demonstrate that E-MSCs do not lose their multipotentiality, we compared the osteogenic and adipogenic differentiation of MSCs extracted from 7-day-old microcapsules with that of control MSCs. Both populations displayed analogous positivity for Alizarin Red staining after 15 days of conditioning with osteogenic stimuli (Supplementary Figure 1a) . Similarly, the staining with Oil Red after adipogenic stimulation showed comparable differentiation Letters to the editor to adipogenic fate (Supplementary Figure 1b) . mRNA expression of differentiation-related genes, such as fatty acid binding protein 4, Osteocalcin and Collagen2a1 did not increase ( Supplementary  Figure 1c) , suggesting that the multipotency of E-MSCs was preserved in vitro.
We next determined the biocompatibility and viability of E-MSCs administered subcutaneously (s.c.) in vivo. Subcutaneous administration was chosen because the procedure is barely traumatic, does not elicit innate immune responses and is clinically applicable.
12 E-MSCs injected s.c. in the back of mice did not leave the inoculation site and remained as a clear cluster with no tissue capsule surrounding them (data not shown). A high percentage of MSCs extracted from these capsules 30 days after inoculation were viable cells (Supplementary Figure 1d) . This Letters to the editor long-term viability may represent an important achievement for the clinical use of MSCs considering that MSCs injected in the circulation are viable for few days only in the homing tissue. 13 Furthermore, their multipotency was preserved as shown by the low levels of mRNA expression of differentiation-related genes (Supplementary Figure 1e) . These results show that E-MSCs are biocompatible and maintain their viability and stem cell properties in vivo over long periods of time.
The ability of E-MSCs to modulate a local, antigen-specific immune response in vivo was then tested. B6 mice were adoptively transferred with CD4 þ CD45.1 þ Ovalbumin-specific T cells obtained from OT2 mice (TCR transgenic for Ovalbumin peptide 323-339) and were immunized 1 day later with Ovalbumin peptide in complete Freund's adjuvant, by s.c. injection into the footpad. On day 2, animals received 0.4 Â 10 6 MSCs intravenously or 0.4 Â 10 6 E-MSCs s.c. Recipient mice were killed at day 4, the popliteal draining LNs (dLNs) were collected and cells were analyzed by flow cytometry (Figure 1c) . Compared with MSC-treated or untreated mice, those treated with E-MSCs showed a decreased cellularity in the dLNs (Figure 1d ) and in absolute numbers of CD4 þ , CD8 þ and CD11c þ cells (Figures 1e-g ). The percentage and the proliferation of Ovalbumin-specific CD4 þ T in dLN were greatly reduced in E-MSC-treated mice in comparison with the other groups (Figures 1h-k) . However, the CD4 þ FoxP3 þ population was not affected by E-MSC transplantation (Figure 1l) .
The fact that, in our experimental system, MSCs injected intravenously could not inhibit T-cell activation is in contrast with a recent report. 3 This difference may be due to the fact that in our study we injected lower numbers of MSCs in a more inflammatory context. At low numbers, E-MSCs may be more efficient than intravenously injected MSCs that get trapped and die in the lungs (described in references [10] [11] [12] [13] and our unpublished observations).
The capacity of E-MSCs to modulate acute GVHD was then tested. Previous studies on mouse models for GVHD have provided conflicting data about the efficacy of MSCs. Whereas in some models repeated administrations of MSCs were required to inhibit moderate GVHD, 5, 14, 15 in others MSCs were found to be ineffective in preventing or treating the disease (reviewed in Tolar et al. 5 ). Irradiated BALB/c mice were transplanted with either syngeneic (control mice) or allogeneic (GVHD mice) cells (Figure 2a) , and the effects of E-MSCs were evaluated. Although E-MSCs had no effect on the increase of the serum levels of CCL8 and soluble tumor necrosis factor receptor 1 (Supplementary Figures 2a and b) , examination of the liver revealed a trend in the decrease of the cumulative histologic score, inflammatory cell infiltration and tissue damage (Supplementary Figure 2c) . The morphological observation (Supplementary Figures 2d and e) and the immunohistochemical detection of CD3 (Supplementary Figure 2f) revealed numerous foci of lymphoid cells infiltrating hepatic lobules in GVHD livers that were reduced upon E-MSCs treatment.
However, the most striking effect was on the survival of transplanted mice. Although GVHD mice that did not receive MSCs died between day 6 and 13 after transplantation, the treatment with E-MSCs s.c., significantly increased survival rate and clinical score of GVHD mice at day 8 ( Figure 2b and c,  respectively) . Notably, in the same experiments, the intravenous injection of MSCs did not modify disease onset, in agreement with previous reports. 5 Increased survival was also obtained with free MSCs injected s.c. (Supplementary Figure 3) , demonstrating that the encapsulation procedure does not modify the immunoregulatory properties of the cells.
In conclusion, the use of encapsulated cells unequivocally demonstrates that MSCs do not require homing to specific organs or cell-cell contacts to control inflammation and that, in this context; their immunosuppressive action is based on the release of soluble factors that may act systemically. Although the molecular identification of such factors will require further substantial effort, possible candidates that have demonstrated to have a role in vivo and that can act at a distance are PGE2 and TSG-6. 16 Both are upregulated by TNF-a, suggesting a level of control based on the inflammatory microenvironment.
From a translational point of view, subcutaneous transplantation of E-MSCs might represent the optimal strategy for therapeutic intervention in inflammatory diseases because it eliminates all potential problems related to stem cell transplantation, such as tumor growth, ectopic engraftment and uncontrolled differentiation. It also circumvents potential risks linked to the stimulation of donor graft rejection in non-myeloablative settings when using allogeneic MSCs (reviewed in Tolar et al. 5 ). Moreover, removable microcapsules would allow a precise dosage over time, an important aspect of MSC-based therapy that at the moment is very difficult to evaluate. Notably, cell encapsulation using alginate is already being tested in clinical trials for Alzheimer's disease and type 1 diabetes (NCT01163825; NCT01379729, www.clinicaltrials.gov), indicating that the translation of our results into the clinic could be rapidly achieved.
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